Controlling cholesterol in microglia alleviates chronic pain ANI | Updated: May 11, 2021 15:45 IST
Washington [US], May 11 (ANI): Researchers at the University of California San Diego School of Medicine, with colleagues elsewhere, have used a mouse model to demonstrate the pivotal role of cholesterol in CIPN, and proposed a novel therapeutic approach to reverse it.
Chemotherapy can induce painful peripheral neuropathy (CIPN), a chronic condition and common adverse effect for cancer patients undergoing treatment. The findings were published in an online issue of the Journal of Experimental Medicine.
The study was a collaboration between the laboratories of senior study author Yury Miller, MD, PhD, professor of medicine, and Tony Yaksh, PhD, professor of anesthesiology and pharmacology, both at UC San Diego School of Medicine. Miller studies cholesterol metabolism and cardiovascular and neuroinflammation. Yaksh specializes in neuropathic pain
University of California - San Diego
Chemotherapy can induce a painful peripheral neuropathy (CIPN), a chronic condition and common adverse effect for cancer patients undergoing treatment. Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used a mouse model to demonstrate the pivotal role of cholesterol in CIPN, and proposed a novel therapeutic approach to reverse it.
The findings are published in the May 10, 2021, online issue of the Journal of Experimental Medicine.
The study was a collaboration between the laboratories of senior study author Yury Miller, MD, PhD, professor of medicine, and Tony Yaksh, PhD, professor of anesthesiology and pharmacology, both at UC San Diego School of Medicine. Miller studies cholesterol metabolism and cardiovascular and neuro inflammation. Yaksh specializes in neuropathic pain.
Operator
Good day ladies and gentlemen and welcome to Oncternal s Therapeutics Inc. first-quarter 2021 financial results call. [Operator instructions] At this time it is my pleasure to turn the floor over to your host Richard Vincent. Sir the floor is yours.
Rich Vincent
Chief Financial Officer
Thank you, Melinda. Good afternoon, everyone, and thank you for joining us today. Joining me on the call this afternoon are our president and CEO, Dr. James Breitmeyer; and our acting CMO, Dr.
Edwina Baskin-Bey. We welcome all of you. Today s call includes a business update and discussion of our 2021 first-quarter financial results which will be followed by Q&A. Today s press release and replay of today s earnings call will be available on the Investor Relations section of Oncternal s website for at least the next 30 days.
$5 Million Gift to Establish New Center for Taiwan Studies
Commitment from alumnus Chiu-Shan Chen Ph.D. ’69 one of the largest to the Division of Arts and Humanities
All photos of Taiwan taken pre-pandemic by Erik Jepsen/University Communications.
Longtime campus supporters Chiu-Shan Chen Ph.D. ’69 and Rufina Chen have committed $5 million to the University of California San Diego, one of the largest individual gifts to the Division of Arts and Humanities.
Contributing to the Campaign for UC San Diego, this gift will establish a new Center for Taiwan Studies within the division, and highlights the alum’s deep commitment to both giving back, and supporting programs that expand cultural understanding of Taiwan and Taiwanese Americans.
Researchers use gene therapy to prevent learning, memory loss in Alzheimer s mouse model
Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, have used gene therapy to prevent learning and memory loss in a mouse model of Alzheimer s disease (AD), a key step toward eventually testing the approach in humans with the neurodegenerative disease.
The findings are published online in advance of the June 11, 2021 issue of
Molecular Therapy-Methods & Clinical Development.
AD is characterized by the accumulation of clumps of misfolded proteins called amyloid plaques and neurofibrillary tau tangles, both of which impair cell signaling and promote neuronal death. Current AD treatments targeting plaques and tangles address only symptoms, which the study s authors say suggests a reversal and cure of AD will likely require a combination of interventional approaches that both decrease aggregating toxins and promote neuronal and synaptic plasticity.